[A20-102] Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2021
Project no.:
A20-102
Commission:
Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adult patients
Patients with NYHA class I + II cardiac failure: hint of considerable added benefit. Patients with NYHA class III cardiac failure: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-101 | Tafamidis (transthyretin amyloidosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G20-03 | Tafamidis (wild-type or hereditary transthyretin amyloid cardiomyopathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A11-31 | Tafamidis - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A21-42 | Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Addendum to Commission A20-102 | Commission completed |
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.